Literature DB >> 16960122

Type 2 diabetes, thiazolidinediones: bad to the bone?

Nelson B Watts, David A D'Alessio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16960122     DOI： 10.1210/jc.2006-1235

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  4 in total

1.  Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone.

Authors:  Oxana P Lazarenko; Sylwia O Rzonca; William R Hogue; Frances L Swain; Larry J Suva; Beata Lecka-Czernik
Journal:  Endocrinology       Date:  2007-03-01       Impact factor: 4.736

2.  The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study.

Authors:  F-Y Hsiao; C D Mullins
Journal:  Diabetologia       Date:  2009-11-27       Impact factor: 10.122

3.  Bone mass and strength in older men with type 2 diabetes: the Osteoporotic Fractures in Men Study.

Authors:  Moira A Petit; Misti L Paudel; Brent C Taylor; Julie M Hughes; Elsa S Strotmeyer; Ann V Schwartz; Jane A Cauley; Joseph M Zmuda; Andrew R Hoffman; Kristine E Ensrud
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

Review 4.  The prince and the pauper. A tale of anticancer targeted agents.

Authors:  Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.